A.Menarini Australia

17 PBAC submissions on file, active 2014–2025. 69% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Febuxostat
  Rheumatology · Not recommended · 2017—
• Anakinra
  Rare disease · Not recommended · 2017—
• Fentanyl citrate
  Pain · Recommended with restriction · 2017—
• Nitisinone
  Metabolic · Not recommended · 2015—
• Ranolazine
  Cardiovascular · Recommended with restriction · 2018—
• Aclidinium bromide
  Respiratory · Recommended with restriction · 2014—
• Aclidinium bromide plus eformoterol fumarate dihydrate
  Respiratory · Recommended with restriction · 2015—
• Benztropine mesylate
  Neurology · Recommended · 2015—
• Elacestrant
  Oncology · Recommended with restriction · 2025—
• Fentanyl
  Pain · Not recommended · 2014other sponsor
• Tagraxofusp
  Haematology · 2023—

Therapy area mix

Activity by year

2014 (5) · 2015 (5) · 2017 (4) · 2018 (1) · 2023 (1) · 2025 (1)

Rejection patterns

Across 5 Not recommended decisions on file.

• 1×No clinical basis to change the level of authority
• 1×current restriction level considered appropriate
• 1×submission provided no evidence to support claim of use outside current restriction.
• 1×Clinical data did not demonstrate superior effectiveness to allopurinol for patient-relevant outcomes (reduction in acute gout attacks
• 1×tophi reduction